Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has provided an announcement.
Hansoh Pharmaceutical Group Company Limited announced that its jointly developed small molecule Bruton’s tyrosine kinase inhibitor, HS-10561 capsules, has received Clinical Trial Approval from the National Medical Products Administration of China. This approval allows the company to proceed with clinical trials for the treatment of chronic spontaneous urticaria, potentially enhancing its position in the pharmaceutical industry and offering new treatment options for patients.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company that focuses on the development, manufacturing, and marketing of innovative and high-quality medicines. The company operates in the pharmaceutical industry, with a market focus on producing small molecule drugs and other therapeutic solutions.
YTD Price Performance: 9.95%
Average Trading Volume: 5,529,672
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$112.8B
Find detailed analytics on 3692 stock on TipRanks’ Stock Analysis page.